LY3561774 for Dyslipidemia

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Dyslipidemia+3 MoreLY3561774 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug to see if it's effective and safe for people with mixed dyslipidemia who are already taking a statin.

Eligible Conditions
  • Dyslipidemia
  • Metabolic Diseases
  • Hyperlipoproteinemia
  • Lipid Metabolism Disorders

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
ARO-ANG 3 Injection
1
LY3819469 Dose 2
2
Olezarsen

Study Objectives

2 Primary · 12 Secondary · Reporting Duration: Up to Day 270

Baseline, Day 180
Percent Change from Baseline for Angiopoietin-like (ANGPTL3)
Percent Change from Baseline for Apolipoprotein (ApoB)
Percent Change from Baseline for Apolipoprotein B (ApoB)
Percent Change from Baseline for High Density Lipoprotein-Cholesterol (HDL-C)
Percent Change from Baseline for Low Density Lipoprotein-Cholesterol (LDL-C)
Percent Change from Baseline for Non-High Density Lipoprotein-Cholesterol (non-HDL-C)
Percent Change from Baseline for Non-High-Density Lipoprotein-Cholesterol (non-HDL-C)
Baseline, Day 270
Percent Change from Baseline for ANGPTL3
Percent Change from Baseline for ApoB
Percent Change from Baseline for HDL-C
Percent Change from Baseline for LDL-C
Triglycerides
Percent Change from Baseline for non-HDL-C
Up to Day 270
Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3561774

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

2
ARO-ANG 3 Injection
2
LY3819469 Dose 2
3
Olezarsen

Trial Design

5 Treatment Groups

LY3561774 Dose 1
1 of 5
LY3561774 Dose 4
1 of 5
LY3561774 Dose 2
1 of 5
LY3561774 Dose 3
1 of 5
Placebo
1 of 5

Experimental Treatment

Non-Treatment Group

175 Total Participants · 5 Treatment Groups

Primary Treatment: LY3561774 · Has Placebo Group · Phase 2

LY3561774 Dose 1
Drug
Experimental Group · 1 Intervention: LY3561774 · Intervention Types: Drug
LY3561774 Dose 4
Drug
Experimental Group · 1 Intervention: LY3561774 · Intervention Types: Drug
LY3561774 Dose 2
Drug
Experimental Group · 1 Intervention: LY3561774 · Intervention Types: Drug
LY3561774 Dose 3
Drug
Experimental Group · 1 Intervention: LY3561774 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3561774
2020
Completed Phase 1
~80

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to day 270

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,466 Previous Clinical Trials
3,135,224 Total Patients Enrolled
4 Trials studying Dyslipidemia
1,051 Patients Enrolled for Dyslipidemia
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Study DirectorEli Lilly and Company
1,258 Previous Clinical Trials
369,220 Total Patients Enrolled
2 Trials studying Dyslipidemia
499 Patients Enrolled for Dyslipidemia

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have fasting LDL-C ≥100 mg/dL (2.59 mmol/L) at screening.
You have a body mass index within the range of 18.5 to 40.0 kg/m², inclusive.

Who else is applying?

What state do they live in?
Pennsylvania100.0%
How old are they?
18 - 65100.0%
What site did they apply to?
Preferred Primary Care Physicians100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top